{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:56:27Z","timestamp":1791928587849,"version":"4.3.4"},"reference-count":0,"publisher":"Association for Research in Vision and Ophthalmology (ARVO)","issue":"7","license":[{"start":{"date-parts":[[2016,6,15]],"date-time":"2016-06-15T00:00:00Z","timestamp":1465948800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Invest. Ophthalmol. Vis. Sci."],"published-print":{"date-parts":[[2016,6,15]]},"DOI":"10.1167\/iovs.15-18795","type":"journal-article","created":{"date-parts":[[2016,6,15]],"date-time":"2016-06-15T15:51:59Z","timestamp":1466005919000},"page":"3138","source":"Crossref","is-referenced-by-count":18,"title":["Blockage of PI3K\/mTOR Pathways Inhibits Laser-Induced Choroidal Neovascularization and Improves Outcomes Relative to VEGF-A Suppression Alone"],"prefix":"10.1167","volume":"57","author":[{"given":"Jie","family":"Ma","sequence":"first","affiliation":[{"name":"Schepens Eye Research Institute Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Sun","sequence":"additional","affiliation":[{"name":"Schepens Eye Research Institute Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco J.","family":"L\u00f3pez","sequence":"additional","affiliation":[{"name":"Ophthalmology Discovery Performance Unit, GlaxoSmithKline, King of Prussia, Pennsylvania, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Adamson","sequence":"additional","affiliation":[{"name":"Ophthalmology Discovery Performance Unit, GlaxoSmithKline, Stevenage, United Kingdom 4Ocular Biology and Therapeutics, UCL Institute of Ophthalmology, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edit","family":"Kurali","sequence":"additional","affiliation":[{"name":"Quantitative Sciences, RD Alternative Discovery & Development, GlaxoSmithKline, King of Prussia, Pennsylvania, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kameran","family":"Lashkari","sequence":"additional","affiliation":[{"name":"Schepens Eye Research Institute Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"27","container-title":["Investigative Opthalmology & Visual Science"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/iovs.arvojournals.org\/article.aspx?doi=10.1167\/iovs.15-18795","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:30:26Z","timestamp":1791927026000},"score":1,"resource":{"primary":{"URL":"http:\/\/iovs.arvojournals.org\/article.aspx?doi=10.1167\/iovs.15-18795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,15]]},"references-count":0,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,6,1]]}},"URL":"https:\/\/doi.org\/10.1167\/iovs.15-18795","relation":{},"ISSN":["1552-5783"],"issn-type":[{"value":"1552-5783","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6,15]]}}}